Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 11/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117892 | 1.00 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL26688568 | 1.00 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL23798791 | 1.00 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL23798790 | 1.00 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| Water SCHEMBL15153123 | 0.99 | HSD11B1 (0.98) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| Water SCHEMBL23777526 | 0.99 | HSD11B1 (0.98) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| Water SCHEMBL15153126 | 0.99 | HSD11B1 (0.98) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3218945 | 0.95 | HSD11B1 (0.90) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3218954 | 0.95 | HSD11B1 (0.90) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL117742 | 0.94 | HSD11B1 (0.89) | HSD11B1CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2846797-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2015-03-18 | — | — | EP | claimed |
| US-8648192-B2 | 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | claimed |
| US-20130303446-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | claimed |
| WO-2013167554-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | WO | claimed |
| US-20130203985-A1 | 2-OXO-1,2-DIHYDROPYRIDIN-4-YLBORONIC ACID DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | US | claimed |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137658-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137660-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250319072-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12329745-B2 | Methods and compositions for treating glucocorticoid excess | SPARROW PHARMACEUTICALS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20100256363-A1 | SYNTHESIS OF INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2183228-A1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010011314-A1 | CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011314-A1 | CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009134400-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134400-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319072-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885CYP2C9 640/4885CYP2C19 440/4885 |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, SHBG | HSD11B1 4/4885CYP2C9 322/4885CYP2C19 123/4885 |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C2, NR3C1, MC2R | HSD11B1 4/4885CYP2C9 388/4885CYP2C19 157/4885 |
| US-12329745-B2 | Methods and compositions for treating glucocorticoid excess | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885CYP2C9 640/4885CYP2C19 440/4885 |
| US-20260137660-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, SHBG | HSD11B1 4/4885CYP2C9 429/4885CYP2C19 178/4885 |
| US-20100256363-A1 | SYNTHESIS OF INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885CYP2C9 721/4885CYP2C19 307/4885 |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C2, NR3C1, MC2R | HSD11B1 4/4885CYP2C9 377/4885CYP2C19 151/4885 |
| US-20260137658-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, NR5A1 | HSD11B1 5/4885CYP2C9 680/4885CYP2C19 253/4885 |
| US-20130203985-A1 | 2-OXO-1,2-DIHYDROPYRIDIN-4-YLBORONIC ACID DERIVATIVES | CYP1B1, OXGR1, ODC1 | HSD11B1 341/4885CYP2C9 49/4885CYP2C19 61/4885 |
| US-20130303446-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | SLC5A1, SLC5A2, G6PC1 | HSD11B1 78/4885CYP2C9 746/4885CYP2C19 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.